Romiplostim N01 for Chemotherapy-induced Thrombocytopenia

Age: 18 years or above, gender not restricted;

Patients who meet the diagnostic criteria for chemotherapy-related thrombocytopenia, and still ineffective after repeated treatment with rhTPO or IL-11 (subjects need to undergo regular rhTPO treatment for at least 14 days after radiotherapy and chemotherapy, with a dose of rhTPO 300u/kg/d or higher, and the platelet count remains less than 30×10^9/L, defined as refractory CTIT);

Patients who have stopped chemotherapy and radiotherapy for more than 1 month;

Patients with platelet count at enrollment < 30×10^9/L;